Ratings Mankind Pharma Limited

Equities

MANKIND

INE634S01028

Market Closed - NSE India S.E. 05:13:53 13/06/2024 pm IST 5-day change 1st Jan Change
2,240 INR +0.68% Intraday chart for Mankind Pharma Limited +3.89% +13.00%

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2026.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • With an expected P/E ratio at 49 and 40.68 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+13.00% 1.07TCr -
+51.54% 78TCr
C+
-7.20% 35TCr
C+
+18.67% 33TCr
B-
+7.48% 29TCr
C+
+16.91% 25TCr
B+
+0.53% 22TCr
A+
+11.06% 22TCr
B-
+3.64% 16TCr
C+
-3.96% 16TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MANKIND Stock
  4. Ratings Mankind Pharma Limited